Aridis Pharmaceuticals, Inc.·4

Dec 11, 5:13 PM ET

KURLAND FRED 4

4 · Aridis Pharmaceuticals, Inc. · Filed Dec 11, 2018

Insider Transaction Report

Form 4
Period: 2018-12-05
KURLAND FRED
Chief Financial Officer
Transactions
  • Award

    Stock Options

    2018-12-05+17,00040,024 total
    Exercise: $8.50Exp: 2028-12-05Common Stock (17,000 underlying)
Footnotes (1)
  • [F1]The shares underlying this stock option vest as follows: in equal annual installments over the 48 months following the date of grant.

Documents

1 file
  • 4
    a4.xmlPrimary

    4